India, July 3 -- In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment for patients in the Democratic Republic of the Congo.
The PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) trial will assess whether two antiviral therapies - a monoclonal antibody (MBP134) and remdesivir - can improve survival among people diagnosed with BVD. It will also evaluate whether combining the two antivirals provides additional benefits.
The trial, sponsored by the World Health Organization, has been coordinated by the Institut National de Recherche Biomedicale in DR Congo, the Institute of Tropical Medicine in ...